⌘K

Home/Filings/4/0001209191-18-020449

4//SEC Filing

Cory David A 4

Accession 0001209191-18-020449

CIK 0001305253other

View on SEC.gov Company Profile

Filed

Mar 15, 8:00 PM ET

Accepted

Mar 16, 8:19 PM ET

Size

5.4 KB

Accession

0001209191-18-020449

Insider Transaction Report

Form 4

Period: 2018-03-14

Eiger BioPharmaceuticals, Inc.EIGR

DirectorPresident and CEO

Transactions

Award
Stock Option (Right to Buy)
2018-03-14+190,000→ 190,000 total
Exercise: $9.50Exp: 2028-03-13→ Common Stock (190,000 underlying)

Footnotes (1)

[F1]The option vests in equal monthly installments over 48 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Eiger BioPharmaceuticals, Inc.

CIK 0001305253

Entity typeother

Related Parties

1

filerCIK 0001670137

Filing Metadata

Form type: 4
Filed: Mar 15, 8:00 PM ET
Accepted: Mar 16, 8:19 PM ET
Size: 5.4 KB

View on SEC.gov